Jaguar Health, Inc. (JAGX): Entry into a Material Definitive Agreement
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Jaguar Health Announces a Special Stock Dividend Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / October 2, 2026 / Jaguar Health, Inc . ( NASDAQ: JAGX ) (“Jaguar” or
How this was made
The 30-second read
Why it matters
The special dividend aims to protect existing shareholders from dilution while the company evaluates strategic alternatives, including a potential NDA filing in mid‑2027.
Market read
Primary disclosure of a corporate action that may affect JAGX share price and investor perception of the company's financial health.
What to watch
Conversion ratio and timing may create short‑term volatility around the November 2 conversion date.
Background
Jaguar Health is a commercial‑stage biotech focused on plant‑derived therapies for rare intestinal failure diseases.
Ticker impact
Jaguar Health filed an 8‑K announcing a special stock dividend of Series R convertible preferred shares to protect against dilution.
likely modest pressure as the market prices in dilution protection and conversion mechanics
Primary SEC filing provides concrete terms; investors will adjust valuation for the upcoming conversion of preferred to common shares.
Market effects
Limited; primarily affects niche biotech/rare‑disease segment.
None beyond the company's share price.
Low
Counterpoint
The dividend could be a red flag for cash constraints, suggesting potential future financing pressures.
Key entities
- companyJaguar Health, Inc.
Issuer of the special stock dividend.
- personLisa Conte
Founder, President and CEO of Jaguar Health.
